Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

691
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
691
Glaucoma: Overview01:25

Glaucoma: Overview

770
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
770
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

577
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
577
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

6.5K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.5K
Visual Agnosia01:12

Visual Agnosia

304
Visual agnosia is a condition characterized by the inability to recognize visually presented objects despite having normal vision. For instance, a person with visual agnosia can describe the shape and color of an object but cannot identify or name it. This impairment does not affect their visual field, acuity, color vision, brightness discrimination, language, or memory. An example of this condition in a social setting is someone at a dinner party asking for "that silver thing with a round...
304

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of hormonal markers in predicting reproductive lifespan in girls with Turner syndrome-a retrospective study.

Journal of the Endocrine Society·2026
Same author

Tolerability and efficacy of full-body head-up tilt sleeping in Parkinson's disease and multiple system atrophy.

NPJ Parkinson's disease·2026
Same author

Regulatory innovation for drug repurposing: Ten proposals to accelerate access and safety.

Drug discovery today·2026
Same author

Menopause-related quality of life five years after salpingectomy with delayed oophorectomy versus Salpingo-Oophorectomy.

Journal of the National Cancer Institute·2026
Same author

The goal attainment scale in primary mitochondrial disease: Construct validity and lessons learned from a randomized controlled trial.

Molecular genetics and metabolism·2026
Same author

Genetic Correlates of Phenotypic Variability in c.5882G>A p.(Gly1961Glu)-Associated Stargardt Disease.

Investigative ophthalmology & visual science·2026

Related Experiment Video

Updated: Sep 13, 2025

Author Spotlight: Assessment of Visual Acuity in Central Vision Loss Through Motion-Based Peripheral Vision Testing
06:25

Author Spotlight: Assessment of Visual Acuity in Central Vision Loss Through Motion-Based Peripheral Vision Testing

Published on: February 23, 2024

713

The Visual Acuity Course in Stargardt Disease.

Jeroen A A H Pas1, Dyon Valkenburg1, Catherina H Z Li1

  • 1From the Department of Ophthalmology (J.A.A.H.P., D.V., C.H.Z.L., P.P.A.D., C.B.H.), Radboud University Medical Center, Nijmegen, the Netherlands; Cognitive Neuroscience Department, Donders Institute for Brain, Cognition and Behaviour (J.A.A.H.P., D.V., C.H.Z.L., R.W.J.C., P.P.A.D., C.B.H.), Radboud University Medical Center, Nijmegen, the Netherlands.

American Journal of Ophthalmology
|July 27, 2025
PubMed
Summary

Visual acuity decline in Stargardt disease type 1 is nonlinear and varies by age of onset. Large sample sizes make visual acuity an impractical primary endpoint for clinical trials.

More Related Videos

Stereoacuity Improvement using Random-Dot Video Games
06:25

Stereoacuity Improvement using Random-Dot Video Games

Published on: January 14, 2020

14.5K
Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss
07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

565

Related Experiment Videos

Last Updated: Sep 13, 2025

Author Spotlight: Assessment of Visual Acuity in Central Vision Loss Through Motion-Based Peripheral Vision Testing
06:25

Author Spotlight: Assessment of Visual Acuity in Central Vision Loss Through Motion-Based Peripheral Vision Testing

Published on: February 23, 2024

713
Stereoacuity Improvement using Random-Dot Video Games
06:25

Stereoacuity Improvement using Random-Dot Video Games

Published on: January 14, 2020

14.5K
Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss
07:12

Development of a Gaze-Contingent Display Framework Designed for Perceptual and Oculomotor Research with Simulated Central Vision Loss

Published on: April 11, 2025

565

Area of Science:

  • Ophthalmology
  • Genetics
  • Clinical Research

Background:

  • Stargardt disease type 1 is a genetic retinal disorder causing progressive vision loss.
  • Understanding the natural history of visual acuity decline is crucial for clinical trial design.

Purpose of the Study:

  • To model the nonlinear progression of visual acuity decline in Stargardt disease type 1.
  • To evaluate variations in decline rates based on age of onset.
  • To assess the suitability of visual acuity as a primary endpoint in clinical trials.

Main Methods:

  • Retrospective natural history study involving 327 patients with genetically confirmed Stargardt disease type 1.
  • Visual acuity data (Snellen/ETDRS charts) converted to LogMAR for analysis.
  • Sigmoid curve modeling to represent nonlinear visual acuity decline across early, intermediate, and late-onset groups.

Main Results:

  • Visual acuity decline rates varied by disease stage, peaking at 0.3 LogMAR (0.227 LogMAR/year).
  • Early-onset and late-onset groups exhibited significantly steeper decline rates than the intermediate-onset group (P < .001).
  • Sample size calculations indicated 139 patients needed for a 3-year trial with 80% treatment effect, assuming a 0.3 LogMAR starting visual acuity.

Conclusions:

  • Visual acuity decline in Stargardt disease type 1 follows a nonlinear trajectory influenced by age of onset.
  • The substantial sample size requirement renders visual acuity impractical as a primary endpoint for clinical trials.
  • The developed models offer valuable tools for patient counseling regarding disease progression.